NCSL 2025 Resources

AdvaMed®, the medtech association, today released the following statements on the White House’s announcement today of a new initiative focused on women’s health research to be led by First Lady Jill Biden. This year, AdvaMed® created a Board-level committee to address health disparities more broadly, led by AdvaMed® Board of Directors member Lishan Aklog, M.D., as well as a Board-level subcommittee on women’s health, led by AdvaMed® Board member Tracy MacNeal. Statements from both medtech leaders follow.

Imagine walking just 10 yards from your front door to the mailbox and becoming so winded, you feel like you might faint. Or imagine your heart beating so chaotically that its chambers don’t empty blood properly, creating clots that could lead to a stroke, yet you have zero symptoms and no idea you’re at risk.

WASHINGTON—AdvaMed, the Medtech Association, is pleased to announce Charles Fleischman as the first-ever recipient of the AdvaMedDx Lifetime of Leadership & Service Award. 

As patient advocates, we’ve witnessed countless stories of hope deferred and lives put on hold while Medicare beneficiaries wait several years for access to breakthrough medical technologies that the FDA has already deemed safe and effective. This unacceptable delay between innovation and access must end. Innovation does not benefit patients without coverage.

WASHINGTON—AdvaMed, the world’s largest trade association representing medtech innovators, today welcomed a letter from U.S. Senators Susan Collins (R-Maine) and Jeanne Shaheen (D-N.H.), co-chairs of the Senate Diabetes Caucus, and U.S. Representatives Diana DeGette (D-Colo.-01) and Gus Bilirakis (R-Fla.-12), co-chairs of the U.S. House Diabetes Caucus, to Centers for Medicare and Medicaid Services (CMS) Administrator Mehmet Oz urging the agency not to finalize a proposal the lawmakers warned could reduce and complicate patient access to continuous glucose monitors (CGMs) and durable insulin pumps.

WASHINGTON—AdvaMed, the MedTech Association, released the following statement from President and CEO Scott Whitaker on the Administration’s announcement of its investigation under Section 232 of the Trade Expansion Act into whether the U.S.’s current level of medtech imports has national security implications:

WASHINGTON—AdvaMed, the medtech association, today thanked the U.S. House Energy and Commerce Health Subcommittee for highlighting the need for Medicare coverage of FDA-authorized breakthrough medtech and releasing a discussion draft of breakthrough coverage legislation at a hearing, “Examining Policies to Enhance Seniors’ Access to Breakthrough Medical Technologies.” 

WASHINGTON—AdvaMed, the medtech association, today welcomed U.S. House of Representatives Committee on Ways and Means passage of legislation providing Medicare coverage of FDA-designated and authorized breakthrough medtech. AdvaMed also urged legislators to add diagnostic tests to the measure, the Ensuring Patient Access to Critical Breakthrough Products Act, H.R. 5343.